LOCALLY ADVANCED LUNG NON-SMALL CELL CARCINOMA
Clinical trials for LOCALLY ADVANCED LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LOCALLY ADVANCED LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for LOCALLY ADVANCED LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug cocktail targets Hard-to-Treat lung cancer
Disease control OngoingThis early-phase study tests a new combination of two drugs, minnelide and osimertinib, for people with advanced non-small cell lung cancer that has a specific gene change (EGFR mutation). The main goal is to find the safest dose and see how the body responds. Only 8 participants…
Matched conditions: LOCALLY ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 08:57 UTC
-
New drug combo targets tough lung cancer in small early trial
Disease control OngoingThis early-phase study is for people with a specific kind of advanced lung cancer (ALK-positive non-small cell lung cancer) that has gotten worse despite prior ALK-targeted therapy. Researchers are testing a combination of two drugs—brigatinib and bevacizumab—to see what dose is …
Matched conditions: LOCALLY ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 26, 2026 08:32 UTC
-
Immunotherapy duo plus radiation shows promise in lung cancer trial
Disease control OngoingThis early-phase trial is testing whether combining two immunotherapy drugs (ipilimumab and nivolumab) with radiation therapy is safe and effective for people with stage II or III non-small cell lung cancer that cannot be removed by surgery. The goal is to see if this approach ca…
Matched conditions: LOCALLY ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 22, 2026 13:53 UTC
-
New combo aims to tame Immunotherapy's side effects in advanced cancers
Disease control OngoingThis study tests whether adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive the combination to see if it is safer and still eff…
Matched conditions: LOCALLY ADVANCED LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:57 UTC